Join the 'Uterine Leiomyomata / Fibroids' group to help and get support from people like you.
Uterine Leiomyomata / Fibroids News
Related terms: Uterine Fibroid, Fibroid
New Insights Into Fibroids Might Lead to Better Treatments
THURSDAY, Dec. 28, 2023 – Hormone therapy is the usual go-to when women develop painful uterine fibroids, but researchers report they are zeroing in on new avenues for treatment. A University of...
'Couch Potato' Lifestyle Could Raise Women's Odds for Fibroids
THURSDAY, Nov. 30, 2023 – Women in a Chinese study who sat for more than six hours each day faced substantially higher odds of developing uterine fibroids before menopause, a new study has found....
Leisure Sedentary Time Linked to Prevalence of Uterine Fibroids
WEDNESDAY, Nov. 29, 2023 – Leisure sedentary time (LST) is independently associated with the prevalence of uterine fibroids (UFs), according to a study published online Nov. 28 in BMJ Open. Yunrui...
Hysterectomy: What It Is, Side Effects & Recovery
FRIDAY, May 19, 2023 – Hysterectomy is the second most common surgery for women in their reproductive years, right after cesarean section. Nearly 68% of these surgeries are done to address...
Fibroids, Endometriosis Tied to Higher Ovarian Cancer Risk
MONDAY, May 15, 2023 – Fibroids are associated with an increased risk for ovarian cancer in both Black and White women, with risk modified by hysterectomy status, according to a study published...
How Fibroids, Endometriosis Affect a Woman's Odds for Ovarian Cancer
THURSDAY, May 4, 2023 – Having uterine fibroids or endometriosis can increase a woman’s risk of developing ovarian cancer, but a new study finds that a hysterectomy can lower that risk for both B...
FDA Approves Myfembree as the First Once-Daily Treatment for Heavy Menstrual Bleeding Associated With Uterine Fibroids
BASEL, Switzerland and NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) – Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has...
FDA Approves Oriahnn (elagolix/estradiol/norethindrone acetate and elagolix) for the Management of Heavy Menstrual Bleeding Due to Uterine Fibroids in Pre-Menopausal Women
NORTH CHICAGO, Ill., May 29, 2020 /PRNewswire/ – AbbVie (NYSE: ABBV), in cooperation with Neurocrine Biosciences, Inc. (Nasdaq: NBIX), announced that the U.S. Food and Drug Administration (FDA)...
Ask a question
To post your own question to this support group, sign in or create an account.